about
Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.Pharmacokinetics, Pharmacodynamics of Bococizumab, a monoclonal antibody to PCSK9, After Single Subcutaneous Injection at 3 Sites [NCT 02043301].Evolocumab for the treatment of hypercholesterolemia.A phase 1 study to evaluate the safety and LDL cholesterol-lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9.The effects of single- and multiple-dose administration of bococizumab (RN316/PF-04950615), a humanized IgG2Δa monoclonal antibody binding proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects treated with and without atorvEffects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin.
P2860
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Bococizumab for the treatment of hypercholesterolaemia.
@en
Bococizumab for the treatment of hypercholesterolaemia.
@nl
type
label
Bococizumab for the treatment of hypercholesterolaemia.
@en
Bococizumab for the treatment of hypercholesterolaemia.
@nl
prefLabel
Bococizumab for the treatment of hypercholesterolaemia.
@en
Bococizumab for the treatment of hypercholesterolaemia.
@nl
P2093
P2860
P1476
Bococizumab for the treatment of hypercholesterolaemia.
@en
P2093
Alberto Corsini
Cesare R Sirtori
Massimiliano Ruscica
Nicola Ferri
P2860
P304
P356
10.1080/14712598.2017.1279602
P407
P577
2017-01-06T00:00:00Z